Schrodinger, Inc. (SDGR) company profile
Close on Nov 13, 2026Market cap $2.21BP/E –Yield –
About Schrodinger
Pharmaceutical Preparations, SIC 2834
Schrödinger, Inc. provides a physics-based computational software platform used to discover and design molecules for therapeutic and materials science applications. The company operates primarily through software licensing and collaborative and proprietary drug discovery programs. Its software products, including Glide, FEP+, and the LiveDesign enterprise informatics platform, assist biopharmaceutical and industrial companies, academic institutions, and government laboratories in modeling molecular interactions, optimizing candidates, and conducting lead optimization. In materials science, Schrödinger offers solutions across organic electronics, semiconductors, aerospace, energy, and chemicals.
The company's commercial software customer base includes leading multinational pharmaceutical firms, biotechnology companies, and academic researchers across more than 1,750 academic institutions worldwide. Direct sales and technical operations span the United States, the European Union, the United Kingdom, Japan, India, and South Korea, supplemented by third-party distribution partners in additional markets including China. The company also maintains a portfolio of collaborative and internal preclinical and clinical drug development programs. Schrödinger's primary corporate offices are not explicitly named in the provided text.
Summary of the business section of Schrodinger's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Schrodinger, Inc.
- Founded
- 1990
- Headquarters
- New York, NY
- Address
- 1540 Broadway, 24th Floor 10036
- Phone
- (503) 299-1150
- Website
- www.schrodinger.com
- Employees
- 850, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Portland, OR
Stock & identifiers
- Ticker
- SDGR
- Exchange
- Nasdaq
- IPO date
- Feb 6, 2020
- Shares outstanding
- 75M, Jul 29, 2026
- Public float
- $1.12B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1490978
- CUSIP
- 80810D103
- ISIN
- US80810D1037
- FIGI
- BBG000T88BN2
- Share class FIGI
- BBG001SZK2K0
- LEI
- 984500044BAE4791E559
- EIN
- 95-4284541
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ramy Farid | President & CEO, Director | 330,824 |
| Paul Jonathan Davie | See Remarks | 18,400 |
| Robert Lorne Abel | See Remarks | 54,219 |
| Yvonne Tran | EVP, CLO & CPO | 52,683 |
| Karen Akinsanya | See Remarks | 101,555 |
| Rachit Jain | EVP & CFO | 50,877 |
| Therese Marie Abrams | VP, Corporate Controller | 19,461 |
| Kenneth Patrick Lorton | EVP, CTO & COO, Software | 89,241 |
| Jenny Herman | CAO | 34,804 |
| Mannix Vartan Aklian | See Remarks | 31,193 |
| Margaret Dugan | Chief Medical Officer | 24,574 |
| Geoffrey Craig Porges | EVP & CFO | 18,185 |
| Richard Friesner | Director | 1,413,618 |
| Rosana Kapeller-Libermann | Director | 25,388 |
| Michael Lynton | Director | 25,388 |
| Nancy Thornberry | Director | 25,388 |
| Gary L. Ginsberg | Director | 25,388 |
| Kralingen Bridget A. van | Director | 19,640 |
| Jeffrey Chodakewitz | Director | 25,388 |
| Gary Sender | Director | 25,388 |
| Arun Oberoi | Director | 25,388 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.08M | $3.21M | $1.95M | $23 | $126 |
| FY2024 | $4.41M | $667.05K | $2.35M | $24 | $101 |
| FY2023 | $3.12M | $9.66M | $2.05M | $45 | $98 |
| FY2022 | $3.92M | -$3.05M | $1.57M | $24 | $95 |
| FY2021 | $8.49M | -$21.06M | $4.06M | $44 | $97 |
| FY2020 | $8.51M | $72.69M | $2.35M | $248 | $116 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Ramy Farid President and Chief Executive Officer | $730.00K | – | $796.50K | $1.97M | $570.86K | $14.81K | $4.08M | -7% |
| Richie Jain Chief Financial Officer | $503.75K | – | $588.51K | $459.46K | $231.90K | $12.31K | $1.80M | – |
| Geoffrey Porges Chief Financial Officer | $317.71K | – | $265.50K | $667.86K | – | $770.84K | $2.02M | -15% |
| Karen Akinsanya President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | $600.00K | – | $331.88K | $834.82K | $331.20K | $13.03K | $2.11M | -23% |
| Mannix Aklian Chief Commercial Officer, Global Head of Software Sales & Marketing | $286.69K | $75.00K | $301.51K | $1.15M | $180.03K | $14.47K | $2.01M | – |
| Yvonne Tran Chief Legal Officer and Chief People Officer | $584.00K | – | $265.50K | $667.86K | $268.64K | $14.81K | $1.80M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 6, 2020
- Offer price
- $17.00
- Securities offered
- 11,882,352
- Gross proceeds
- $202.00M
- Exchange
- Nasdaq
- First trading day
- Feb 6, 2020
- First-day close
- $28.64+68.5%
- Lock-up ends (est.)
- Aug 4, 2020
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 3, 2026, we had 850 full-time employees, including a total of 363 employees with Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 6, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 31, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?